Rheumatology
Inflammation is responsible for systemic bone loss in patients with seropositive rheumatoid arthritis treated with rituximab
Mie Jin Lim, Kyong-Hee Jung, Seong-Ryul Kwon, Won Park
Korean J Intern Med. 2023;38(6):912-922. Published online October 23, 2023
Background/Aims: We investigated the effect of rituximab on systemic bone metabolism in patients with seropositive rheumatoid arthritis (RA).
Methods: Twenty seropositive patients with RA were enrolled and administered one cycle of rituximab. If RA became active for > 6 months after the first ritux..
|